The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Open accessAbstract
// Xiaoman Li 1,* , Changjing Wu 1,* , Nianci Chen 2 , Huadi Gu 3 , Allen Yen 4 , Liu Cao 1 , Enhua Wang 3,5 and Liang Wang 3,5 1 Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, China 2 Class 9 of the 97th Clinical Medicine of Seven-Year Program, China Medical University, Shenyang, China 3 Department of Pathology, The College of Basic Medical Sciences, China Medical University, Shenyang, China 4 School of Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America 5 Department of Pathology, The First Affiliated Hospital of China Medical University, Shenyang, China * These authors have contributed equally to this work Correspondence to: Liang Wang, email: // Keywords : glioblastoma, EGFR, PI3K/Akt/mTOR pathway, targeted therapy Received : December 05, 2015 Accepted : February 24, 2016 Published : March 07, 2016 Abstract Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation of many downstream signal pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sensitive mTOR-complex (mTOR) pathway. Here we explored the reason why inhibition of the pathway may serve as a compelling therapeutic target for the disease, and provided an update data of EFGR and PI3K/Akt/mTOR inhibitors in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812
Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
Powis, G., Bonjouklian, R., Berggren, M. M., Gallegos, A. C., Abraham, R. T., Ashendel, C. L., Zalkow, L. H., Matter, W. F., Dodge, J. A., & Grindey, G. B. (1994) · PubMed · Cited by 687
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 585
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
Szerlip, N. J., Pedraza, A., Chakravarty, D., Azim, M., McGuire, J., Fang, Y., Ozawa, T., Holland, E. C., Huse, J. T., Jhanwar, S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114033109 · Cited by 538
An expanding role for mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.007 · Cited by 523
Glioblastoma: From Molecular Pathology to Targeted Treatment
Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130324 · Cited by 518
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Dowling, R. J. O., Topisirovic, I., Fonseca, B. D., & Sonenberg, N. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 454
Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M. J., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 454
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 440
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 420
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Oncogenic EGFR Signaling Networks in Glioma
Huang, P. H., Xu, A. M., & White, F. M. (2009) · Science Signaling · doi:10.1126/scisignal.287re6 · Cited by 363
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Markman, B., Dienstmann, R., & Tabernero, J. (2010) · Oncotarget · doi:10.18632/oncotarget.188 · Cited by 355
PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy
Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., & Donner, D. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108302200 · Cited by 351
Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313
Interplay between FOXO, TOR, and Akt
Hay, N. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.013 · Cited by 311
Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., Geoffroy, F. J., Arusell, R., Kitange, G., Jenkins, R. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0612 · Cited by 277
Using the molecular classification of glioblastoma to inform personalized treatment
Olar, A., & Aldape, K. D. (2014) · The Journal of Pathology · doi:10.1002/path.4282 · Cited by 261
Liu, T.-J., Koul, D., LaFortune, T., Tiao, N., Shen, R. J., Maira, S.-M., Garcia-Echevrria, C., & Yung, W. K. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0160 · Cited by 253
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Friedman, A. H., Herndon, J. E., Marcello, J., Norfleet, J. A., McLendon, R. E., Sampson, J. H., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9950-0 · Cited by 232
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J., Herndon, J. E., Mathe, A., Hamilton, M., Rich, J. N., Norfleet, J. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq099 · Cited by 231
Peereboom, D. M., Shepard, D. R., Ahluwalia, M. S., Brewer, C. J., Agarwal, N., Stevens, G. H. J., Suh, J. H., Toms, S. A., Vogelbaum, M. A., Weil, R. J., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0067-2 · Cited by 205
Hegi, M. E., Diserens, A.-C., Bady, P., Kamoshima, Y., Kouwenhoven, M. C. M., Delorenzi, M., Lambiv, W. L., Hamou, M.-F., Matter, M. S., Koch, A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0048 · Cited by 194
Momota, H., Nerio, E., & Holland, E. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1042 · Cited by 177
Halatsch, M.-E., Schmidt, U., Behnke-Mursch, J., Unterberg, A., & Wirtz, C. R. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.01.003 · Cited by 174
Koul, D., Fu, J., Shen, R., LaFortune, T. A., Wang, S., Tiao, N., Kim, Y.-W., Liu, J.-L., Ramnarian, D., Yuan, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1558 · Cited by 171
Wen, P. Y., Chang, S. M., Lamborn, K. R., Kuhn, J. G., Norden, A. D., Cloughesy, T. F., Robins, H. I., Lieberman, F. S., Gilbert, M. R., Mehta, M. P., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not247 · Cited by 171
Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis
Joy, A. M., Beaudry, C. E., Tran, N. L., Ponce, F. A., Holz, D. R., Demuth, T., & Berens, M. E. (2003) · Journal of Cell Science · doi:10.1242/jcs.00712 · Cited by 153
mTORC2 in the center of cancer metabolic reprogramming
Masui, K., Cavenee, W. K., & Mischel, P. S. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.04.002 · Cited by 142
Sami, A., & Karsy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0800-5 · Cited by 141
Hartmann, W., Digon-Söntgerath, B., Koch, A., Waha, A., Endl, E., Dani, I., Denkhaus, D., Goodyer, C. G., Sørensen, N. S., Wiestler, O. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2187 · Cited by 141
Chakravarti, A., Dicker, A. P., & Mehta, M. P. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.092 · Cited by 138
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature11903 · Cited by 135
Current clinical development of PI3K pathway inhibitors in glioblastoma
Wen, P. Y., Lee, E. Q., Reardon, D. A., Ligon, K. L., & Yung, W. K. A. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos117 · Cited by 134
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma
Koul, D., Shen, R., Kim, Y., Kondo, Y., Lu, Y., Bankson, J. A., Ronen, S. M., Kirkpatrick, D. L., Powis, G., & Yung, W. K. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop058 · Cited by 130
Chemically targeting the PI3K family
Knight, Z. A., & Shokat, K. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350245 · Cited by 125
Phase II study of PX-866 in recurrent glioblastoma
Pitz, M. W., Eisenhauer, E. A., MacNeil, M. V., Thiessen, B. A., Easaw, J. C., Macdonald, D. R., Eisenstat, D. D., Kakumanu, A. S., Salim, M., Chalchal, H. I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou365 · Cited by 121
Choi, E. J., Cho, B. J., Lee, D., Hwang, Y., Chun, S. H., Kim, H. H., & Kim, I. A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-17 · Cited by 117
Carson, J. D., Aller, G. V., Lehr, R. V., Sinnamon, R. H., Kirkpatrick, R. B., Auger, K. R., Dhanak, D., Copeland, R. A., Gontarek, R. R., Tummino, P. J., et al. (2007) · Biochemical Journal · doi:10.1042/bj20070681 · Cited by 116
Targeted Therapy for Malignant Glioma Patients: Lessons Learned and the Road Ahead
Huang, T., Sarkaria, S. M., Cloughesy, T. F., & Mischel, P. S. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.008 · Cited by 93
Knobbe-Thomsen, C. B., Trampe-Kieslich, A., & Reifenberger, G. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00660.x · Cited by 92
Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway
Stauffer, F., Maira, S.-M., Furet, P., & Garcı́a-Echeverrı́a, C. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.018 · Cited by 87
Hainsworth, J. D., Shih, K. C., Shepard, G. C., Tillinghast, G. W., Brinker, B. T., & Spigel, D. R. (2012) · PubMed · Cited by 84
Jhanwar‐Uniyal, M., Gillick, J. L., Neil, J. A., Tobias, M. E., Thwing, Z. E., & Murali, R. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.09.004 · Cited by 79
Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility
Jhanwar-Uniyal (2009) · International Journal of Oncology · doi:10.3892/ijo_00000386 · Cited by 79
Stücklin, A. G., Fattet, S., Fischer, B. E., Shalaby, T., Jackson, S. P., Schoenwaelder, S. M., Grotzer, M. A., Delattre, O., & Arcaro, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0385 · Cited by 77
Inhibition of PI3K-Akt-mTOR Signaling in Glioblastoma by mTORC1/2 Inhibitors
Fan, Q.-W., & Weiss, W. A. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-430-8_22 · Cited by 67
Luchman, H. A., Stechishin, O. D. M., Nguyen, S. A., Lun, X. Q., Cairncross, J. G., & Weiss, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3389 · Cited by 56
A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy
Westhoff, M., Karpel‐Massler, G., Brühl, O., Enzenmüller, S., Ferla-Brühl, K. L., Siegelin, M. D., Nonnenmacher, L., & Debatin, K. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-32 · Cited by 50
Role of Phosphatidylinositol 3,4,5-Trisphosphate in Cell Signaling
Riehle, R. D., Cornea, S., & Degterev, A. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-6331-9_7 · Cited by 50
Wu, S., Bi, J., Cloughesy, T. F., Cavenee, W. K., & Mischel, P. S. (2014) · PubMed Central · doi:10.7497/j.issn.2095-3941.2014.04.004 · Cited by 45
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055
Marshall, G. B., Howard, Z., Dry, J. R., Fenton, S. E., Heathcote, D., Gray, N. M., Keen, H. G., Logié, A., Holt, S. V., Smith, P. D., et al. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390456 · Cited by 40
Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma
Gao, Q., Lei, T., & Ye, F. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.806484 · Cited by 39
Messaoudi, K., Clavreul, A., & Lagarce, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.014 · Cited by 36
Novel Mutations of Epidermal Growth Factor Receptor in Localized Prostate Cancer
Diah, A. D. (2006) · Frontiers in bioscience · doi:10.2741/1986 · Cited by 35
Akt signaling is required for glioblastoma maintenance in vivo.
Robinson, J. P., VanBrocklin, M. W., McKinney, A. J., Gach, H. M., & Holmen, S. L. (2011) · Europe PMC (PubMed Central) · Cited by 30
Advances with phospholipid signalling as a target for anticancer drug development.
Powis, G., Berggren, M. I., Gallegos, A. C., Frew, T., Hill, S., Kozikowski, A. P., Bonjouklian, R., Zalkow, L. H., Abraham, R. T., & Ashendel, C. L. (1995) · Acta Biochimica Polonica · doi:10.18388/abp.1995_4893 · Cited by 18
Effects of cotransfection of antisense‐EGFR and wild‐type PTEN cDNA on human glioblastoma cells
Tian, X., Zhang, Y., Du, J., Fang, W., Ng, H., & Zheng, J. (2006) · Neuropathology · doi:10.1111/j.1440-1789.2006.00679.x · Cited by 15
Cited by
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian, T., Li, X., & Zhang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030755 · Cited by 576
Self-citationPrognostic and Predictive Biomarkers in Gliomas
Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910373 · Cited by 340
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Szopa, W., Burley, T. A., Kramer-Marek, G., & Kaspera, W. (2017) · BioMed Research International · doi:10.1155/2017/8013575 · Cited by 320
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines · doi:10.3390/biomedicines7030069 · Cited by 279
Metadata
- Authors
- Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-03-07
- Volume
- 7
- Issue
- 22
- Pages
- 33440-33450
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2296095373
- Cited by
- 542
- References
- 88
- FWCI
- 23.47
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.